Compare Ginkgo Bioworks Holdings Inc (DNA) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs SkyWest Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.33 (market cap $505.73M), while SkyWest Inc trades at $106.17 (market cap $4.19B). The key difference: SkyWest Inc is far larger — about 8.3× Ginkgo Bioworks Holdings Inc's market cap, and SkyWest Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | SKYW | |
|---|---|---|
Market Cap | $505.73M | $4.19B |
Sector | Health | Technology |
52-Week High | $16.14 | $123.72 |
52-Week Low | $5.48 | $78.40 |
Enterprise Value | $607.68M | $5.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
SkyWest (SKYW) trades at $106.38, down 1.2% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $109.33. The stock shows solid fundamentals with a P/E of 10.72 and ROE of 15.34%, though Q2 2026 earnings missed estimates. Recent news highlights executive stock sales alongside institutional interest and a 7.7% post-earnings rally noted by Zacks Investment Research on 2026-07-27.
The outlook is cautiously positive given analyst buy ratings (56.25%) and undervalued metrics, but risks include fuel cost volatility from Iran war impacts (New York Post, 2026-07-07) and mixed earnings performance. Upside potential exists if Q3 2026 meets its $3.13 EPS expectation, balancing insider selling with buyback support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
